Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Coherus Oncology (NASDAQ:CHRS) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02, FiscalAI reports. The company had revenue of $14.27 million during the quarter, compared to the consensus estimate of $15.90 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%.

Coherus Oncology Stock Up 6.2%

Shares of CHRS traded up $0.05 during trading hours on Monday, hitting $0.82. The company had a trading volume of 2,188,007 shares, compared to its average volume of 1,515,357. Coherus Oncology has a one year low of $0.73 and a one year high of $2.62. The company has a current ratio of 1.77, a quick ratio of 1.70 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $126.32 million, a PE ratio of -0.79 and a beta of 1.03. The company’s fifty day moving average price is $1.14 and its two-hundred day moving average price is $1.51.

Analysts Set New Price Targets

A number of research firms have weighed in on CHRS. HC Wainwright assumed coverage on shares of Coherus Oncology in a research report on Thursday, October 29th. They set a “buy” rating on the stock. Weiss Ratings upgraded Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.00.

About Coherus Oncology

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.